ABL1(E255K) |
ABL1 |
TK |
Mutation confers imatinib-resistance in chronic myeloid leukemia (CML). |
Lancet. 359, 487-491 (2002). |
ABL1(F317I) |
ABL1 |
TK |
Mutation confers dasatinib-resistance in cell culture. |
Proc Natl Acad Sci USA. 102, 3395–3400 (2005); Blood. 108, 2332-2338 (2006). |
ABL1(F317L) |
ABL1 |
TK |
Mutation confers imatinib- and dasatinib-resistance in chronic myeloid leukemia (CML). |
Blood. 100, 1014-1018 (2002); J Clin Oncol. 24, e51-52 (2006). |
ABL1(H396P) |
ABL1 |
TK |
Mutation confers imatinib- and dasatinib-resistance in chronic myeloid leukemia (CML). |
Lancet. 359, 487-491 (2002). |
ABL1(M351T) |
ABL1 |
TK |
Mutation confers imatinib-resistance in chronic myeloid leukemia (CML). |
Blood. 100, 1014-1018 (2002). |
ABL1(Q252H) |
ABL1 |
TK |
Mutation confers imatinib-resistance in chronic myeloid leukemia (CML). |
Cancer Cell. 2, 117-125 (2002). |
ABL1(T315I) |
ABL1 |
TK |
Mutation confers imatinib-, dasatinib- and nilotinib resistance in chronic myeloid leukemia (CML). |
Science. 293, 876-880 (2001); Lancet. 359, 487-491 (2002). |
ABL1(Y253F) |
ABL1 |
TK |
Mutation confers imatinib-resistance in chronic myeloid leukemia (CML). |
Proc Natl Acad Sci USA. 99, 10700-10705 (2002). |
BRAF(V600E) |
BRAF |
TKL |
Activating mutation found in malignant melanoma. |
Nature. 417, 949-954 (2002). |
EGFR(E746-A750del) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
N Engl J Med. 350, 2129-2139 (2004); Science. 304, 1497-1500 (2004); Proc Natl Acad Sci USA. 101, 13306-13311 (2004). |
EGFR(G719C) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
N Engl J Med. 350, 2129-2139 (2004). |
EGFR(G719S) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
Science. 304, 1497-1500 (2004). |
EGFR(L747-E749del, A750P) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
Science. 304, 1497-1500 (2004). |
EGFR(L747-S752del, P753S) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
Science. 304, 1497-1500 (2004). |
EGFR(L747-T751del,Sins) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
N Engl J Med. 350, 2129-2139 (2004); Science. 304, 1497-1500 (2004). |
EGFR(L858R) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
N Engl J Med. 350, 2129-2139 (2004); Science. 304, 1497-1500 (2004); Proc Natl Acad Sci USA. 101, 13306-13311 (2004). |
EGFR(L858R,T790M) |
EGFR |
TK |
T790M mutation confers ge? tinib- and erlotinib- resistance in non-small-cell lung cancer (NSCLC). |
N Engl J Med. 352, 2136 (2005); PLoS Med. 2, e73 (2005). |
EGFR(L861Q) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
N Engl J Med. 350, 2129-2139 (2004). |
EGFR(S752-I759del) |
EGFR |
TK |
EGFR inhibitor sensitizing mutation in non-small-cell lung cancer (NSCLC). |
Science. 304, 1497-1500 (2004). |
EGFR(T790M) |
EGFR |
TK |
T790M mutation confers ge? tinib- and erlotinib- resistance in non-small-cell lung cancer (NSCLC). |
Cancer Res. 66, 7854-7858 (2006). |
FGFR3(G697C) |
FGFR3 |
TK |
Activating mutation found in oral squamous cell carcinoma. |
Int J Cancer. 117, 166-168 (2005). |
FLT3(D835H) |
FLT3 |
TK |
Activating mutation found in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). |
Blood. 97, 2434-2439 (2001); Br J Haematol. 113, 983-988 (2001). |
FLT3(D835Y) |
FLT3 |
TK |
Activating mutation found in acute myeloid leukemia (AML). |
Blood. 97, 2434-2439 (2001); Br J Haematol. 113, 983-988 (2001). |
FLT3(ITD) |
FLT3 |
TK |
Activating mutation found in acute myeloid leukemia (AML). |
Leukemia. 10, 1911-1918 (1996). |
FLT3(K663Q) |
FLT3 |
TK |
Activating mutation found in acute myeloid leukemia (AML). |
Leukemia. 20, 2008-2014 (2006). |
FLT3(N841I) |
FLT3 |
TK |
Activating mutation found in acute myeloid leukemia (AML). |
Blood. 104, 1855-1858 (2004). |
FLT3(R834Q) |
FLT3 |
TK |
Activating mutation found in acute myeloid leukemia (AML). |
Cancer Cell. 12, 501–513 (2007). |
KIT(A829P) |
KIT |
TK |
A829P mutation confers imatinib-resistance in gastrointestinal stromal tumors (GIST). |
J. Clin. Oncol. 24, 4764-2774 (2006). |
KIT(D816H) |
KIT |
TK |
Activating mutation found in systemic mastocytosis, D816H confers imatinib-resistance in gastrointestinal 1542-stromal tumors (GIST). |
Oncogene. 20, 4528-4536 (2001); Am J Pathol. 163, 305-313 (2004); Proc Natl Acad Sci USA. 106, 1547 (2009). |
KIT(D816V) |
KIT |
TK |
Activating mutation found in systemic mastocytosis and acute myeloid leukemia. |
Nature Gen. 12, 312-314 (1996); Blood 107, 3463-3468 (2006). |
KIT(L576P) |
KIT |
TK |
Mutation found in malignant melanoma. |
Clin Cancer Res. 14 6821-6828 (2008). |
KIT(V559D) |
KIT |
TK |
Activating mutation found in gastrointestinal stromal tumors (GIST). |
Clin. Cancer Res. 11, 3668-3677 (2005). |
KIT(V559D,T670I) |
KIT |
TK |
T670I mutation confers imatinib-resistance in gastrointestinal stromal tumors (GIST). |
Clin. Cancer Res. 11, 4182-4190 (2005). |
KIT(V559D,V654A) |
KIT |
TK |
V654A mutation confers imatinib-resistance in gastrointestinal stromal tumors (GIST). |
Clin. Cancer Res. 11, 4182-4190 (2005). |
LRRK2(G2019S) |
LRRK2 |
TKL |
Activating mutation found in Parkinson’s disease. |
Proc Natl Acad Sci USA. 102, 16842-16847 (2005). |
MET(M1250T) |
MET |
TK |
Mutation found drug-resistant papillary renal carcinomas. |
Proc Natl Acad Sci USA. 95, 14379-14383 (1998); Oncogene. 20, 5493-5502 (2001). |
MET(Y1235D) |
MET |
TK |
Activating mutation found in lymph node metastases of head and neck squamous-cell carcinomas. |
Oncogene. 19, 1547-1555 (2000); Biochemistry. 44, 14110-14119 (2005). |
PIK3CA(C420R) |
PIK3CA |
LIPID |
Activating mutation found in diverse cancers. |
Cancer Res. 65, 4562-4567 (2005); Proc Natl Acad. Sci USA. 104, 5569-5574 (2007). |
PIK3CA(E542K) |
PIK3CA |
LIPID |
Activating mutation found in diverse cancers. |
Proc Natl Acad Sci USA. 103, 1475-1479 (2006); Proc Natl Acad Sci USA. 104, 5569-5574 (2007). |
PIK3CA(E545A) |
PIK3CA |
LIPID |
Activating mutation found in diverse cancers. |
Proc Natl Acad Sci USA. 104, 5569-5574 (2007). |
PIK3CA(E545K) |
PIK3CA |
LIPID |
Activating mutation found in diverse cancers. |
Proc Natl Acad Sci USA. 104, 5569-5574 (2007). |
PIK3CA(I800L) |
PIK3CA |
LIPID |
A potential hotspot for resistance mutations. |
Cancer Cell. 14, 180–192 (2008). Resistant to PI-103 but sensitized to NVP-BEZ-235. |
PIK3CA(H1047L) |
PIK3CA |
LIPID |
Activating mutation found in diverse cancers. |
Proc Natl Acad Sci USA. 104, 5569-5574 (2007). |
PIK3CA(H1047Y) |
PIK3CA |
LIPID |
Activating mutation found in diverse cancers. |
Proc Natl Acad Sci USA. 104, 5569-5574 (2007). |
PIK3CA(M1043I) |
PIK3CA |
LIPID |
Activating mutation found in diverse cancers. |
Cancer Res. 65, 4562-4567 (2005). |
PIK3CA(Q546K) |
PIK3CA |
LIPID |
Activating mutation found in diverse cancers. |
Proc Natl Acad Sci USA. 104, 5569-5574 (2007). |
RET(M918T) |
RET |
TK |
Activating mutation found in multiple endocrine neoplasias and familial medullary thyroid carcinomas. |
Cancer Res. 63, 5559-5563 (2003); Cancer Res. 66, 10741-10749 (2006). |
RET(V804L) |
RET |
TK |
Activating mutation found in multiple endocrine neoplasias and familial medullary thyroid carcinomas. |
Oncogene. 23, 6056-6063 (2004). |
RET(V804M) |
RET |
TK |
Activating mutation found in multiple endocrine neoplasias and familial medullary thyroid carcinomas. |
Oncogene. 23, 6056-6063 (2004). |